Company Overview and News
In 2012, my family said thanks but no thanks to Coca-Cola after the company offered to acquire a controlling interest in THP Beverage Group, the family-owned business my parents founded in 1994.
German, Japanese sovereign bond yields haven’t kept pace. While continuing QE over there (some would call market manipulation) plays a role, liquid markets do indeed point to divergent trends.
Bingo! With nothing actually “new” serving as a prompt, the market logged another winning day on Thursday anyway. The S&P 500’s 0.78% gain left it at a record-high close of 2930.75.
GE GEC LEN DRI NVDA HPE MU GNE MS
Every now and then investors can let emotions get the better of them, buying (or selling) a stock for all the wrong reasons. Advanced Micro Devices (NASDAQ:AMD) has been one of those stocks. While its turnaround is real, the bulk of the 200%+ rally AMD stock has dished out since mid-April was rooted in hype rather than results.
AMD NVDA MS INTC
We're looking at as many as 13 IPOs in the upcoming week, raising up to $1.1 billion. Even if 2 are postponed, it will still be the busiest September by IPO count since 2000. The 13 offerings are relatively small: none plan to raise more than $200 million, and eight have insider buying. As we noted in our Fall Preview, US activity is being boosted by biotechs and Chinese deals, and this week will see 5 and 3, respectively.
PRNB YMAB MS
With the markets at all-time highs, it is prime season for initial public offerings (IPOs) and companies can get more bang for their buck. There were a couple major IPOs this past week that lived up to the hype and then some, and one that floundered.
EB DB BNPQY LLY BNPQF BNPZY XYF ELAN MS
Solarwinds Corp. has filed for an initial public offering, seeking to sell up to $500 million worth of shares, according to a filing. The Austin, Texas-based IT infrastructure software provider went public in 2009, and it was acquired and taken private by private-equity firms Silver Lake Partners and Thoma Bravo seven years later. "Today, we are a very different company than we were in early 2016," having added more products recently, the company said in its prospectus.
SWI DTK MS
Good morning, everybody. Thank you very much for coming, and welcome to the Smiths Group presentation of our annual results. My name is Jemma Spalton, and I'm the Director of Investor Relations. Just a few housekeeping points before we get started. We're not expecting a fire drill, so if the alarms do sound, please exit through the fire exits to the left and right. And I'd also be grateful if you are able to spend a couple of moments just reading and digesting our disclaimer slide.
SMIN DB SMGZY SMGKF ICUI MS
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the closing of its public offering in the United States and an offering in Europe only to qualified investors (within the meaning of Directive 2003/71/EC, as amended) (the Offering) of 3,475,000 American Depositary Shares (ADSs) at a price to the public of $86.
Two diametrically opposite reports from premier financial institutions on the Indian market have left many retail investors perplexed. While one changed its bullish stance (since 2014) to neutral, the other has maintained its optimism on Indian markets.
2018-09-21 zacks - 1
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), EOG Resources (EOG) and Simon Property Group (SPG). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
WFCNP TXN NFLX MS WFC UNP EOG S SPG
More than half a billion pounds in fees for bankers, lawyers, accountants and public relations firms are at stake in the next 24 hours as Comcast takes on with 21st Century Fox and Disney in the final battle for Sky.
DB PJT MS
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET